Anhui HygeianCells EE001 vs HucMSC intramyocardial therapy
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Cardiac cell therapy · full Heart Failure pipeline
Anhui HygeianCells EE001
Developed by Anhui HygeianCells BioMedical
NCT06884111 · Phase 1 · completed
Only 6 people received the drug, all in a single open, unblinded group with no placebo or comparison arm, so any change seen cannot be attributed to the drug with confidence. No results have been posted yet.
No aligned efficacy figure on record for this race.
HucMSC intramyocardial therapy
Developed by Tasly Pharmaceutical Group
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07265349 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Heart Failure
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Anhui HygeianCells EE001 | HucMSC intramyocardial therapy |
|---|---|---|
| CV death or HF hospitalisation | —Not reported | —Not reported |
| HF hospitalisation | —Not reported | —Not reported |
| CV death | —Not reported | —Not reported |
| KCCQ clinical summary, change | —Not reported | —Not reported |
CV death or HF hospitalisation
- Anhui HygeianCells EE001
- —Not reported
- HucMSC intramyocardial therapy
- —Not reported
HF hospitalisation
- Anhui HygeianCells EE001
- —Not reported
- HucMSC intramyocardial therapy
- —Not reported
CV death
- Anhui HygeianCells EE001
- —Not reported
- HucMSC intramyocardial therapy
- —Not reported
KCCQ clinical summary, change
- Anhui HygeianCells EE001
- —Not reported
- HucMSC intramyocardial therapy
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Anhui HygeianCells EE001: no structured comparison results are available for Heart Failure.
HucMSC intramyocardial therapy: no structured comparison results are available for Heart Failure.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anhui HygeianCells EE001's landscape · HucMSC intramyocardial therapy's landscape